Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3062% below fair value
$15.73−0.48 (-2.96%)
Close on Nov 13, 2026Market cap $2.11BP/E 6.9Yield –
Aurinia Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Aurinia Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was $175.72M, up 96.4% year over year. For fiscal 2025 it was $124.36M, up 742.7% from the year before. The highest annual figure on record is $124.36M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $124.36M | +742.7% |
| FY2024 | Dec 31, 2024 | $14.76M | – |
| FY2023 | Dec 31, 2023 | -$80.04M | – |
| FY2022 | Dec 31, 2022 | -$108.76M | – |
| FY2021 | Dec 31, 2021 | -$177.97M | – |
| FY2020 | Dec 31, 2020 | -$102.92M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $40.20M | +16.2% |
| Q2 FY2026 | Jun 30, 2026 | $51.18M | +105.1% |
| Q1 FY2026 | Mar 31, 2026 | $46.24M | +73.2% |
| Q4 FY2025 | Dec 31, 2025 | $38.10M | +1093.3% |
| Q3 FY2025 | Sep 30, 2025 | $34.61M | +108.0% |
| Q2 FY2025 | Jun 30, 2025 | $24.95M | +649.2% |
| Q1 FY2025 | Mar 31, 2025 | $26.70M | – |
| Q4 FY2024 | Dec 31, 2024 | $3.19M | – |
| Q3 FY2024 | Sep 30, 2024 | $16.64M | – |
| Q2 FY2024 | Jun 30, 2024 | $3.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.41M | – |
See a number that looks wrong?